Biosimilar Solutions, Inc. enters License and Development Agreement with Reliance Life Sciences Ltd
Biosimilar Solutions Inc., (“BSS”) a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets, announced that it has entered a license and development agreement with Reliance Life Sciences Ltd to commercialize Filgrastim and PEG-Filgrastim in the US. BSS has industry veterans with decades of experience in pioneering biologics companies, such as Amgen and Genentech, where they were responsible for leading, and in some cases, establishing these organizations’ core capabilities in process development, protein manufacturing and analytical research and development. Senior members of the team have contributed to the filing of over 100 Investigational New Drug applications, or INDs, and over 40 marketing applications, including those for Enbrel, the originator product for our lead biosimilar product candidate.
“We are pleased to have entered this relationship with Reliance,” said Robert Salcedo, CEO. “These products will provide affordable options to doctors in the oncology support space.”
Pegfilgrastim (Neulasta), a pegylated form of the recombinant human G-CSF analog, filgrastim, is commonly used in the prevention of chemotherapy-induced neutropenia, which is characterized by an abnormally low level of neutrophils and other white blood cells that aid in the defense against infections. The worldwide G-CSF market is composed of short-acting G-CSFs, such as filgrastim, lenograstim and TBO-filgrastim, and extended duration pegylated G-CSFs such as pegfilgrastim.
About Biosimilar Solutions, Inc. : Biosimilar Solutions is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets, lasered focus on affordability, increasing patient access with uncompromising Quality. Our team includes industry veterans with decades of experience in pioneering biologics companies, such as Amgen and Genentech, where they were responsible for leading, and in some cases establishing, these organizations’ core capabilities in process development, protein manufacturing and analytical research and development. Senior members of our internal team have contributed to the filing of over 100 Investigational New Drug applications, or INDs, and over 40 marketing applications, including those for Enbrel, the originator product for our lead biosimilar product candidate.
About Reliance Life Sciences Ltd : Reliance Life Sciences is a research-driven organization developing business opportunities in bio-therapeutics (plasma proteins, biosimilars and novel proteins), pharmaceuticals (later-generation, oncology generics), clinical research services, regenerative medicine (stem cells therapies) and molecular medicine. Reliance Life Sciences is part of the Promoter Group of Reliance Industries Limited. Reliance Life Sciences is a fully integrated, life sciences industry player, with in-house capabilities in research, pre-clinical and clinical development, process development, quality management, commercial-scale manufacturing and marketing. Reliance Life Sciences has launched five of the world’s first biosimilars, has the largest number of biosimilars in the market in India, and the highest number of biosimilars under development globally.